Entourage Health Cannabis Reports 9% YoY Increase In Q1 Revenue, Positive EBITDA And 'Substantial Growth'
Entourage Health Cannabis Reports 9% YoY Increase In Q1 Revenue, Positive EBITDA And 'Substantial Growth'
Canadian cannabis producer and distributor Entourage Health Corp. (TSXV:ENTG) (OTCQX:ETRGF) (FSE:4WE) announced its first quarter financial results on Tuesday for the three months ended March 31, 2024.
加拿大大麻生產商和分銷商Entourage Health Corp.（多倫多證券交易所股票代碼：ENTG）（OTCQX: ETRGF）（FSE: 4WE）週二公佈了截至2024年3月31日的三個月的第一季度財務業績。
The Toronto-based company reported a total revenue of CA$16.4 million ($12 million) (net revenue of CA$12.7 million, before excise duties and discounts), representing a 9% year-over-year increase.
這家總部位於多倫多的公司報告的總收入爲1,640萬加元（合1200萬美元）（扣除消費稅和折扣前的淨收入爲1,270萬加元），同比增長9％。
"Entourage's first quarter results are a testament to our robust financial health and strategic approach to business operations, positioning us for success throughout 2024," George Scorsis, the company's chair and CEO said. "With defined infrastructure and supply agreements in place, we are well-positioned to continue delivering the accelerated growth we have already seen develop in Q1."
該公司董事長兼首席執行官喬治·斯科西斯表示：“Entourage的第一季度業績證明了我們穩健的財務狀況和業務運營戰略方針，爲我們在2024年取得成功做好了準備。”“有了明確的基礎設施和供應協議，我們完全有能力繼續實現我們在第一季度已經看到的加速增長。”
Q1 2024 Financial Highlights
2024 年第一季度財務摘要
- Gross profit before changes in fair value amounted to CA$5.8 million, up from CA$3 million in the prior year's period.
- Gross margin before changes in fair value was 45%, up from 25% in the same quarter of fiscal 2023.
- Loss and comprehensive loss was CA$6.3 million, down from CA$9.5 million in the corresponding quarter of last year.
- EBITDA (non-IFRS measure) came in positive at CA$533, 000 compared to a negative EBITDA of CA$3.9 million in the prior year's period.
- Cash and cash equivalents were CA$9.4 million and working capital was CA$152.9 million as of March 31, 2024, down from CA$11.2 million and up from CA$146.9 million, respectively, during the period ended March 31, 2023.
- 公允價值變動前的毛利爲580萬加元，高於去年同期的300萬加元。
- 公允價值變動前的毛利率爲45％，高於2023財年同期的25％。
- 虧損和綜合虧損爲630萬加元，低於去年同期的950萬加元。
- 息稅折舊攤銷前利潤（非國際財務報告準則指標）爲正數，爲53.3萬加元，而去年同期的息稅折舊攤銷前利潤爲負390萬加元。
- 截至2024年3月31日，現金及現金等價物爲940萬加元，營運資金爲1.529億加元，分別低於截至2023年3月31日的1,120萬加元和1.469億加元。
As yet another earnings reporting season wraps up it is important to understand what these figures mean for the future of the industry. Hear directly for top executives, investors and policymakers at the 19th Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9. Get your tickets now before prices surge by following this link.
隨着又一個業績期的結束重要的是要了解這些數字對該行業的未來意味着什麼。在將於10月8日至9日在芝加哥舉行的第19屆Benzinga大麻資本會議上，直接聽取高層管理人員、投資者和決策者的意見。點擊此鏈接，立即在價格飆升之前獲取門票。
"Our team's relentless focus on efficient execution has led to a solid performance, reflected in improved profitability and a significant increase in EBITDA, marking the first positive quarter," Scorsis continued. "We are also seeing substantial growth in our adult-use business as we continue to announce and launch a range of innovative products across Canada set to generate ongoing interest and excitement among consumers."
斯科西斯繼續說：“我們的團隊對高效執行的不懈關注帶來了穩健的業績，這反映在盈利能力的提高和息稅折舊攤銷前利潤的大幅增長上，這標誌着第一個積極的季度。”“隨着我們繼續在加拿大各地宣佈和推出一系列創新產品，我們的成人用途業務也將大幅增長，這些產品將引起消費者的持續興趣和興奮。”
ETRGF Price Action
ETRGF 價格走勢
Entourage's shares traded 38.6% higher at CA$0.0132 per share at the market close on Friday.
週五收盤時，Entourage的股價上漲了38.6％，至每股0.0132加元。
Related News
相關新聞
- Cannabis Co. Entourage Health Reports 126% YoY Increase In 2023 Gross Profit, Cuts Losses Significantly
- 大麻公司Entourage Health報告稱，2023年毛利同比增長126％，大幅減少虧損
- Canadian Cannabis Co. Entourage Health Q3 Revenue Slides 8.8% YoY – But Margins Sore, Losses Decline
- 加拿大大麻公司Entourage Health第三季度收入同比下降8.8％，但利潤率上升，虧損下降
- Entourage Health Q1 Revenue Declines 4.8% YoY, What About Adjusted EBITDA?
- Entourage Health第一季度收入同比下降4.8％，調整後的息稅折舊攤銷前利潤呢？
譯文內容由第三人軟體翻譯。